KRON Stock Overview
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Kronos Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.95 |
| 52 Week High | US$2.29 |
| 52 Week Low | US$0.73 |
| Beta | 1.83 |
| 1 Month Change | -25.20% |
| 3 Month Change | -19.49% |
| 1 Year Change | -28.57% |
| 3 Year Change | -96.19% |
| 5 Year Change | n/a |
| Change since IPO | -96.49% |
Recent News & Updates
Recent updates
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?
Jan 19
We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate
Aug 21We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully
Feb 22Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?
Nov 01Kronos Bio, Invivoscribe to develop companion diagnostic for leukemia drug entospletinib
Aug 16Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?
Jul 07We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely
Feb 01How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?
Mar 03Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares
Jan 09
Kronos Bio EPS misses by $4.10
Nov 18Shareholder Returns
| KRON | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.8% | -2.5% | -3.2% |
| 1Y | -28.6% | -3.7% | 19.3% |
Return vs Industry: KRON underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: KRON underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| KRON volatility | |
|---|---|
| KRON Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KRON's share price has been volatile over the past 3 months.
Volatility Over Time: KRON's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 63 | Norbert Bischofberger | www.kronosbio.com |
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Kronos Bio, Inc. Fundamentals Summary
| KRON fundamental statistics | |
|---|---|
| Market cap | US$57.69m |
| Earnings (TTM) | -US$112.67m |
| Revenue (TTM) | US$6.29m |
9.1x
P/S Ratio-0.5x
P/E RatioIs KRON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRON income statement (TTM) | |
|---|---|
| Revenue | US$6.29m |
| Cost of Revenue | US$0 |
| Gross Profit | US$6.29m |
| Other Expenses | US$118.96m |
| Earnings | -US$112.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.87 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,791.87% |
| Debt/Equity Ratio | 0% |
How did KRON perform over the long term?
See historical performance and comparison